AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01558115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study
Study NCT01558115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab
Description: The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study
Study NCT01558115 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study
Study NCT02661204 — intervention group
Intervention type: DEVICE
Intervention: Automated breast ultrasound examination (ABUS)
Description: Automated breast ultrasound examination
Study NCT01195818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAS Inhibitors
Description: Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
Study NCT04054206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-166
Description: MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
Study NCT02140970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
Study NCT02140970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
Study NCT04199065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Good Practice Guidelines implementation
Description: Implementation of Good Practice Guidelines on the framework of the Best Practice Spotlight Organization in Spain (CCEC® / BPSO®), that allows a standardized methodology for providing care and registering indicators.
Study NCT04106128 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound examination
Description: Measuring the thickening fraction by diaphragmatic ultrasound of acute diaphragmatic dysfunction in patients admitted for acute respiratory distress
Study NCT02575729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone
Description: Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
Study NCT02575729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone
Description: Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
Study NCT00634140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: ezetimibe 10 mg daily for 4 to 6 weeks
Study NCT00634140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for 4-6 weeks
Study NCT04487392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen vaginal cream group (group A)
Description: The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home: 1 intravaginal applicator at night, daily for 2 weeks, followed by 2 times a week, on alternate days (Monday - Thursday) for another 2 weeks.
Study NCT04487392 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photobiomodutation group (group B)
Description: The participants selected for group B will be undergo photobiomodulation with red LED. With the participant in the lithotomy position, the speculum will be introduced into the vaginal canal and a vaginal wash with 0.9% saline will be performed to remove secretions. Afterwards, the speculum will be removed and the device with a red LED inserted up to about 6 cm from the introitus. A non-lubricated condom will be used in the LED device for patient protection. Sessions will take place once a week for 4 weeks.
Study NCT03435484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm A
Description: Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
Study NCT03220646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abemaciclib
Description: abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.
Study NCT03220646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abemaciclib
Description: 200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery. Upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.
Study NCT00430989 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nitrous Oxide
Description: General anaesthesia with the inclusion of Nitrous Oxide at 70%
Study NCT00430989 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Nitrous Oxide
Description: General anaesthesia with no use of Nitrous Oxide
Study NCT04687293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HUBER (LPG Systems, France)
Description: The HUBER® device consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed. It also comprises, two large handles with force sensors, mounted on a movable column. Its originality is based on its capacity to capture simultaneously the subjects' balance, core stability, core strength and total body strength; and adapt the training accordingly. Indeed, the platform interferes with the balance of the patient who must continually adjust his/her posture by exerting isometric pushing and pulling efforts with the arms. As a result, the device provides postural and muscle adaptation with visual feedback. Due to the constant adaptation of the device, it is thought to enhance muscular strength and improve neuromuscular coordination simultaneously.
Study NCT01833494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Study NCT03056235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELAPR002f
Description: 30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid
Study NCT03056235 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline control
Study NCT00585988 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hip Resurfacing System
Description: This arm will utilize a hip resurfacing system.
Study NCT00585988 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: M2a-Magnum™ Large Metal Articulation
Description: This arm will utilize the M2a-Magnum™ implant system.
Study NCT00603941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017
Description: At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
Study NCT00603941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
Study NCT03792555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paltusotine
Description: Paltusotine, capsules, once daily by mouth
Study NCT03792555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, capsules, once daily by mouth
Study NCT03203577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initiation of mechanical ventilation
Description: In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.
Study NCT03203577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Initiation of mechanical ventilation
Description: In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.
Study NCT01789086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
Study NCT01789086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
Study NCT02448992 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hippocampal-sparing WBRT
Study NCT04744220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Training Program (exercises)
Description: Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session. The patients will start with breathing exercises, then relaxation exercises, warm-up exercises, asanas (posture exercises) and finally the yoga training program will be completed with deep relaxation technique.
Study NCT04074070 — intervention group
Intervention type: OTHER
Intervention: Ultrasound examination
Description: Ultrasound examination of joints, tendons and entheses.
Study NCT01692106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: Per Oral Endoscopic Myotomy (POEM)
Description: lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
Study NCT04430608 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dexcom G6
Description: The investigational device is a CGM Dexcom G6. The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. The device-system consists of a sensor, the Dexcom G6 device/sender, and connects to a smart device like a cellphone. The Dexcom G6 CGM system is probably the most precise system on the market and with no need for daily calibration with finger prick glucose. The Dexcom G6 sensor can last for 10 days without calibration and is approved for diabetes treatment decision making. Dexcom G6 has been extensively tested and is safe and approved even for pregnant women.~The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC.
Study NCT04430608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: The investigational device is a CGM Dexcom G6. The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. The device-system consists of a sensor, the Dexcom G6 device/sender, and connects to a smart device like a cellphone. The Dexcom G6 CGM system is probably the most precise system on the market and with no need for daily calibration with finger prick glucose. The Dexcom G6 sensor can last for 10 days without calibration and is approved for diabetes treatment decision making. Dexcom G6 has been extensively tested and is safe and approved even for pregnant women.~The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC.
Study NCT04122989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MS-SUPPORT
Description: MS-SUPPORT is a shared decision making tool designed to be used by patients and providers.
Study NCT01861704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyric
Description: Extended wear hearing instrument
Study NCT01861704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyric2
Description: Extended wear hearing instrument
Study NCT04420832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment
Description: Se above
Study NCT04420832 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-surgical treatment
Description: See above
Study NCT03435484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm B
Description: Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
Study NCT02280304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inner Resources for Veterans (IRV)
Description: Mindfulness and breath-focused mantra therapy which uses techniques that encourage present moment attention for the purpose of improving self-monitoring and self-regulation
Study NCT02280304 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Essential Skills therapy
Description: This active comparator is adapted from a therapy utilized at multiple VAs as a psychoeducational AND symptom management treatment for PTSD. In it, participants learn about mTBI and PTSD symptoms and coping information for PTSD.
Study NCT01606800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2b
Description: Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
Study NCT01606800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Ribavirin 200 mg capsules administered orally daily based on weight
Study NCT02036697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 4.5
Description: Bupivacaine hyperbaric, 4.5 mg
Study NCT02036697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 9
Description: Bupivacaine hyperbaric, 9 mg
Study NCT02036697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine 150 mcg.
Study NCT02036697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: morphine 150 mcg.
Study NCT02036697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 15 mcg
Study NCT02943317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A - VS-6063
Description: Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
Study NCT02943317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A - Avelumab
Description: Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
Study NCT04381416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEAD treatment
Description: up to two 30-min endometrial ablation sessions using the IUB SEAD™ device, in a hospital outpatient clinic
Study NCT02035605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-AT3SC
Description: Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
Study NCT02035605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study NCT01074788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mind body therapy
Description: mind-body therapy includes guided imagery, relaxation techniques, mediation and touch therapy.
Study NCT01477255 — intervention group
Intervention type: BEHAVIORAL
Intervention: iPad
Description: The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.
Study NCT02987192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pen type 27 gauge needles
Description: minimally invasive group patients will receive pen type 27 gauge needles.
Study NCT02987192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cutting type 22 gauge needles
Description: traditional group patients will receive cutting type 22 gauge needles.
Study NCT03955575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 6 MG/ML
Description: Liraglutide as injections.
Study NCT03955575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam
Description: 3 x 625 miligram 2 times a day.
Study NCT00629096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow cells
Description: Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter
Study NCT05150912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: strching neck
Study NCT01599793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Given PO
Study NCT01599793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01599793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo MRI
Study NCT04522466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: Hydroxychloroquine (HCQ) will be administered as usual practice: dosage is adjusted to maintain a concentration between 1 and 2 mg/L.~Measure pharmacokinetics and pharmacodynamics of Hydroxychloroquine (HCQ).
Study NCT03285542 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DERMABOND
Description: DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey)
Study NCT03285542 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Staples
Description: staples for skin closure
Study NCT00746655 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,
Study NCT00746655 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcatheter Arterial Chemoembolization (TACE)
Description: . Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
Study NCT02115828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Study NCT03036176 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Play-based family centered stimulation
Description: Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
Study NCT03036176 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: On the other hand, the control SAM group did not receive the guided psychomotor/psychosocial stimulation services although they had access to the playground facilities. Both the intervention and the control groups received all the routine medical care and dietary rehabilitation services at the hospital.
Study NCT00634075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-fatty acids (Omegaven)
Description: The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.